NCT06030817

99mTc-CNDG Injection in the Diagnosis of Malignant Tumors

A Prospective Study to Explore the Performance and Efficacy of 99mTc-CNDG Injection in Malignant Tumors

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: Peking Union Medical College Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

Currently, 18F-fluorodeoxyglucose (18F-FDG) is the most widely used tumor imaging agent in clinical practice. However, the production of 18F requires accelerators and is associated with relatively high diagnostic costs, which to some extent limits its widespread clinical application. In comparison to Positron Emission Tomography (PET), Single Photon Emission Computed Tomography (SPECT) devices are more abundant and offer lower diagnostic expenses. With the utilization of Cadmium Zinc Telluride (CZT) crystals in SPECT and advancements in image reconstruction techniques, the resolution and sensitivity of SPECT is continually improving. Therefore, the development of a simplified and cost-effective novel SPECT tumor imaging agent holds significant practical significance. This study involved the design and synthesis of a glucose-derived ligand with a linker containing seven methylene units and an isonitrile group (CN7DG). The CN7DG ligand was labeled with 99mTc to prepare a more lipophilic 99mTc-CN7DG complex, aiming to investigate a novel SPECT imaging agent for tumor imaging.

Conditions

• Malignant Tumor

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	99mTc-CNDG SPECT/CT	Explore the imaging characteristics of 99mTc-CNDG and its diagnostic efficacy in tumor patients.

Timeline

• Start date: 2023-08-11
• Primary completion: 2025-08-31
• Completion: 2025-12-31
• First posted: 2023-09-11
• Last updated: 2023-09-11

Locations

1 site across 1 country: China